BioTime Cultura da Companhia

Mr. Russell L. Skibsted serves as Chief Financial Officer of AgeX Therapeutics, Inc. Mr. Skibsted has been the Chief Financial Officer of BioTime, Inc. since November 16, 2015. Mr. Skibsted served as the Chief Financial Officer of OncoCyte Corporation since November 2015. He served as the Chief Financial Officer of Asterias Biotherapeutics, Inc. since August 14, 2016. He is a seasoned executive with over 25 years of experience in finance, acquisitions, partnering, marketing and operations, with companies ranging from start-ups to a Fortune 5, including over 10 years with Chief Financial Officer responsibilities in public life science companies. He has significant private equity, public market, operations and transaction experience with both public and private companies. He served as an Acting Chief Financial Officer of Asterias Biotherapeutics, Inc. since March 14, 2016 until August 14, 2016. He joined BioTime from Proove Biosciences, Inc. where he served as Chief Financial Officer since 2014. He served as the Chief Financial Officer and Executive Vice President at Pharmagen, Inc., from June 2014 to June 30, 2014. From 2013 to 2014, Mr. Skibsted served as Managing Director and Chief Financial Officer of RSL Ventures, where he provided financial consulting services to public and private companies in the life sciences sector. He served as the Chief Financial Officer and Senior Vice President of Aeolus Pharmaceuticals Inc., from February 2011 to May 31, 2013 and also served as its Principal Accounting Officer and Secretary until May 31, 2013. He served as the Chief Financial Officer and Vice President of Talon Therapeutics, Inc. from November 15, 2004 to January 1, 2006 and as its Secretary from November 2004 to January 1, 2006. where he led the process of bringing it public and completed two financings. He served as Senior Vice President and Chief Business Officer of Spectrum Pharmaceuticals, Inc. from 2006 to 2009. At Spectrum, he led global strategy, mergers and acquisitions, licensing, fund raising and investor relations. During his tenure at Spectrum, he completed numerous financings, including one of the 2008 largest biopharma partnering transactions for a non-platform technology. He was a Partner and served as the Chief Financial Officer of Asset Management Ventures. Mr. Skibsted served as a Partner and Chief Financial Officer of Asset Management Company where he oversaw the financial and administrative functions, public and private portfolios and aviation operations. He worked at GE Capital Services' Structured Finance Group, running business development in the western United States. As a member of the Corporate Development team at Pinkerton's Inc. where he spearheaded the implementation of its acquisitions and corporate partnering department. He was a Principal at NewCap Partners, Inc. He co-founded two successful startups in the real estate industry. He managed the Johnson family office and the Franklin & Catherine Johnson Foundation. Mr. Skibsted served as a Director of TCSI Corporation since October 2001. He holds a BA in Economics from Claremont McKenna College and an MBA from the Stanford Graduate School of Business.

Mr. Michael H. Mulroy, also known as Mike, serves as the President of Mulroy Advisors, LLC. Mr. Mulroy has been the Chief Executive Officer and President at Asterias Biotherapeutics, Inc since June 26, 2017. He has experience as a strategic planner and as legal counsel and member of a senior management team of a growing biopharmaceutical company. Mr. Mulroy has experience in corporate finance and investor relations. He served as a Senior Advisor to CamberView Partners, LLC. Mr. Mulroy served as Executive Vice President of Strategic Affairs and General Counsel of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc until September 2014. He served as an Executive Vice President of Strategic Affairs at Questcor Pharmaceuticals, Inc. since February 17, 2014. Mr. Mulroy served as General Counsel and Secretary of Questcor Pharmaceuticals, Inc. since January 2011 and corporate counsel since 2005. At Questcor, Mr. Mulroy served in various capacities from January 2011 to September 2014. He served as the Chief Financial Officer of Questcor Pharmaceuticals, Inc. from January 2011 to February 17, 2014; as Executive Vice President from July 31, 2013 to February 17, 2014 and Principal Accounting Officer from September 26, 2011 to February 17, 2014. He was a Partner of Stradling Yocca Carlson & Rauth, P.C since 2004. He served at Stradling Yocca from 2003 to 2011, where he represented Questcor and other publicly-traded companies. From 1997 to 2003, Mr. Mulroy was an Investment Banker at Merrill Lynch and Citigroup, where he advised healthcare companies and other clients across a range of industries in connection with corporate finance and strategic transactions. He has been an Independent Director of BioTime, Inc. since October 06, 2014. He has been Director of Asterias Biotherapeutics, Inc. since June 26, 2017. He serves as a Director of privately-held Magtrol Inc. He serves as a Director of AgeX Therapeutics, Inc. He served as an Independent Director of Comarco, Inc. from July 21, 2011 to August 25, 2014. Mr. Mulroy is a Member of the State Bar of California and the Orange County Bar Association, Business Section. He is a business consultant. He earned his J.D. Degree from the University of California, Los Angeles and his B.A. in Economics from the University of Chicago.

Andrea Park serves as the VP Finance and Controller of BioTime. Andrea started at BioTime in Jan of 2016. Andrea currently resides in the San Francisco Bay Area.

Deborah Andrews serves as the Director (Audit Committee Chair) of BioTime. Deborah started at BioTime in April of 2014. Deborah currently resides in the Greater Los Angeles Area.

Francois Binette serves as the Senior Vice President, Global Head of Research and Development of BioTime. Francois started at BioTime in January of 2016. Francois currently resides in the San Francisco Bay Area.

Brandi Roberts serves as the Chief Financial Officer of BioTime. Brandi started at BioTime in January of 2019. Brandi currently resides in the Greater San Diego Area.